Related Experiment Video
Updated: Jul 11, 2026

Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
Prenatal and early postnatal treatment in 3-phosphoglycerate-dehydrogenase deficiency
T J de Koning1, L W J Klomp, A C C van Oppen
1Department of Metabolic Diseases, University Medical Centre Utrecht, Netherlands. t.dekoning@wkz.azu.nl
Abstract:
3-phosphoglycerate-dehydrogenase (3-PGDH) deficiency is an L-serine biosynthesis disorder, characterised by congenital microcephaly, severe psychomotor retardation, and intractable seizures. We report prenatal diagnosis of an affected fetus by DNA mutation analysis. Ultrasound assessment showed a reduction in fetal head circumference from the 75th percentile at 20 weeks' gestation to the 29th percentile at 26 weeks. L-serine was then given to the mother, which resulted in an enlarged fetal head circumference to the 76th percentile at 31 weeks. At birth, the girl's head circumference was normal, and at 48 months' follow-up, her psychomotor development has been unremarkable. 3-PGDH deficiency is an inborn metabolic error that can be successfully treated antenatally.
Related Concept Videos
Diabetes Mellitus: Type 2 and Gestational
Acute Pancreatitis II: Clinical Manifestations and Management
Pathophysiology of Diabetes
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility, suggesting a...
Nephrotic Syndrome III : Nursing Management
Type I Diabetes III: Clinical Manifestations
Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis

